---
title: "FDA grants rare paediatric designation to Vanda’s CMT2S therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292060929.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-08T09:15:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292060929.md)
  - [en](https://longbridge.com/en/news/292060929.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292060929.md)
---

# FDA grants rare paediatric designation to Vanda’s CMT2S therapy

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [VNDA.US](https://longbridge.com/en/quote/VNDA.US.md)

## Related News & Research

- [Vanda shifts into high gear with Schumacher IndyCar sponsorship](https://longbridge.com/en/news/292938888.md)
- [HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder](https://longbridge.com/en/news/293791898.md)
- [ANALYSIS-Hims & Hers stands to gain if the FDA loosens restrictions on peptides](https://longbridge.com/en/news/293593520.md)
- [Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson disease](https://longbridge.com/en/news/293470001.md)
- [DIA’s 10-year shortfall: How a 186.7% return masks a $128K hidden cost](https://longbridge.com/en/news/293107308.md)